Natera to participate in UnitedHealthcare network

LabPulse.com staff writers
Jul 13, 2022
2019 10 09 17 32 0093 Dna Cancer Cell 400

Natera on Thursday announced that it has been selected to participate in UnitedHealthcare's Preferred Laboratory Network (PLN), effective July 1.

According to UnitedHealthcare's website, its Preferred Lab Network consists of contracted independent, free-standing laboratory care providers that have met higher standards for access, cost, data, quality, and service based on a rigorous application and review process.

Natera offers cell-free DNA (cfDNA) testing and has performed more than 3 million cfDNA tests worldwide since its inception. The tests help patients and their providers make critical healthcare decisions in oncology, women's health, and organ health, Natera said.

Latest in Point-of-Care Testing
Credit: National Institute of Allergy and Infectious Diseases (NIAID)
Scout secures CARB-X grant to advance diagnostic test development
April 22, 2024
Blood collection on the Babson Diagnostics hand-warmer.
Babson adds hand-warming to blood testing mini-draws in Texas pharmacies
April 16, 2024
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
Hands Shaking2 Social
Labcorp acquires BioReference Health assets
March 28, 2024
Related Stories
Dna Cancer Cell Social
Cancer
Natera awarded VA contract for MRD testing and monitoring
2019 07 27 00 04 3609 Breast Cancer Cell 400
Clinical Utility
Natera presents colorectal, breast cancer data at ESMO 2022
2019 10 09 23 45 4810 Lab Nipt Test 400
FDA Submission
Natera files presubmission with FDA for NIPT test
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in Point-of-Care Testing
Scout secures CARB-X grant to advance diagnostic test development
By LabPulse.com staff writers
Scout, formerly Uh Oh Labs, will advance its point-of-care (POC) diagnostic test for sexually transmitted infections (STIs) with a new $1 million accelerator grant.
April 22, 2024
Credit: National Institute of Allergy and Infectious Diseases (NIAID)
Babson adds hand-warming to blood testing mini-draws in Texas pharmacies
By LabPulse.com staff writers
Austin, TX-based Babson Diagnostics said it has received positive feedback for its hand-warmer, which is used as part of a finger-stick blood sample collection device in retail pharmacies.
April 16, 2024
Blood collection on the Babson Diagnostics hand-warmer.
FDA clears another blood-based TBI POC test
By LabPulse.com staff writers
Abbott furthers its point-of-care (POC) assay for measuring traumatic brain injury biomarkers from whole blood.
April 1, 2024
Brain Abstract Social
Labcorp acquires BioReference Health assets
By LabPulse.com staff writers
Labcorp and Opko Health subsidiary BioReference Health have announced that they have made an agreement for Labcorp to acquire certain of BioReference Health’s assets.
March 28, 2024
Hands Shaking2 Social
FDA LDT oversight battle: Are we close?
By Liz Carey
New directions in laboratory developed test (LDT) regulation appeared closer to final rule-making with the March 1 Office of Management and Budget (OMB) acceptance of the LDT final rule, pending regulatory review: a flurry of final rule-making thoughts.
March 6, 2024
Omb Final Rule Laboratory Developed Tests March124
Quest Diagnostics seeks to get a jump on PFAS testing in communities
By Liz Carey
Researchers often use people’s blood PFAS levels as a proxy for exposure to perfluoroalkyl and polyfluoroalkyl substances, the "forever chemicals" found in certain products and the environment.
February 13, 2024
This U.S. Geological Survey (USGS) map shows the number of PFAS detected in tap water samples from select sites across the nation. The findings are based on a USGS study of samples taken between 2016 and 2021 from private and public supplies at 716 locations. The map does not represent the only locations in the U.S. with PFAS. (Source: USGS, public domain.)
Roche signs $350M deal to buy POC technology from LumiraDx
By LabPulse.com staff writers
Roche has entered into a definitive agreement to purchase point-of care (POC) technologies from LumiraDx for $295 million, with an additional payment of up to $55 million to fund the POC diagnostics platform business until the transaction closes.
January 3, 2024
Hands Shaking Deal Social
Quest Diagnostics launches test panel for novel psychoactive substances
By LabPulse.com staff writers
The new "confirmatory testing service" will use definitive liquid chromatography with advanced tandem mass spectrometry-based testing to establish NPS misuse.
December 19, 2023
Quest Diagnostics Newsroom Media Gallery Photo Social
FDA plans to increase oversight of LDTs garner strong response
By Nick Paul Taylor
Plans to increase U.S. Food and Drug Administration (FDA) oversight of laboratory-developed tests (LDTs) have drawn a strong response from trade groups, individuals, and organizations.
November 17, 2023
Fda Sign Dc Social
Talis Biomedical to lay off 90% of workforce, pursue strategic alternatives
By LabPulse.com staff writers
POC testing company Talis Biomedical has announced that it will lay off 90% of its employees and has begun exploring strategic alternatives.
November 15, 2023
Layoff Woman Belongins
Polygenic risk score tests don’t meet expectations, U.K. study shows
By Matt Limb
Polygenic risk scores “perform poorly in screening and prediction of common disease,” failing to identify nearly 90% of patients who develop disease, according to a U.K. study.
October 26, 2023
Dna Sequencing Genome Social
U.K. researchers recommend routine diabetes screening in EDs
By Matt Limb
Diabetes screening should be introduced for patients attending hospital emergency departments (EDs) to prompt earlier treatment where necessary and reduce major health risks, say researchers.
October 10, 2023
Lab Hb A1c Diabetes Social
Page 1 of 41
Next Page